EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ ( POXIPEN) trial protocol

Marie Buzzi iD, Jonathan Epstein, Zahi Hatem, Nadine Juge, Charles Mazeaud, Jean-Louis Lemelle, Nicolas Berte

BJU International · 2026

DOI: 10.1111/bju.70058 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BJU International, 2026. Verfasst von Marie Buzzi und 6 weiteren Autor:innen. Beteiligte Einrichtung: CHRU-Nancy, INSERM, CIC, Epidémiologie Clinique, Université de Lorraine, Nancy, France. Hauptthemen laut MEDLINE: Mandelic Acids, Muscarinic Antagonists, Spinal Dysraphism, Urinary Bladder, Neurogenic. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Farco Pharma, Association Nationale Spina Bifida Handicaps, French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery. Given the risk of repeated general anaesthesia in children, there is a need for non‐invasive treatment for young patients who do not respond to or have adverse effects from oral anticholinergic treatment. The ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial aims to assess the efficacy of intra‐vesical oxybutynin on bladder capacity in a sample of French children with neurogenic bladder. Study Design The POXIPEN is a multicentre, randomised, double‐blind, placebo‐controlled trial. Endpoints The primary outcome is change in maximal bladder capacity after treatment. Secondary outcomes include changes in voiding, urodynamic and ultrasound parameters. We will also assess changes on quality of life and usability of the product. Patients and Methods We aim to randomly assign 60 children with neurogenic bladder secondary to spina bifida and deemed non‐responders to first‐line treatment with oral anticholinergics, to receive intravesical oxybutynin (IVO) or placebo for 4 weeks. Recruitment will start in September 2025. It will be the first prospective study to evaluate the efficacy of IVO in children, with a high level of evidence provided by its design. If IVO proves effective, it could lengthen the delay in therapeutic escalation to invasive procedures, thereby reducing the risk of complications associated with general anaesthesia in children with neurogenic bladder.

Trial registration

This trial is registered with the European Union (EU) Clinical Trials Information System (CTIS) under EU CT Number: 2022–501 902–36‐00 (approved 09.01.2025) and ClinicalTrials.gov under identifier NCT07027020 (registered 18.06.2025).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mandelic AcidsMuscarinic AntagonistsSpinal DysraphismUrinary Bladder, NeurogenicAdolescentChildChild, PreschoolFemaleHumansMaleAdministration, IntravesicalDouble-Blind MethodMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeUrinary BladderUrodynamicsClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

neurogenic bladderpaediatric surgeryrandomised controlled trialspina bifidaurology

Substanzen

Mandelic AcidsMuscarinic Antagonistsoxybutynin

Autor:innen und Institutionen

  • CHRU-Nancy, INSERM, CIC, Epidémiologie Clinique, Université de Lorraine, Nancy, France.
  • Inserm, INSPIIRE, Université de Lorraine, Nancy, France.
  • CHRU-Nancy, Pediatric Surgery Department, Université de Lorraine, Nancy, France.
  • CHRU-Nancy, Urology Department, Université de Lorraine, Nancy, France.

ORCID-Profile: Marie Buzzi

Förderung

  • Farco Pharma
  • Association Nationale Spina Bifida Handicaps
  • French Ministry of Health

Zitieren

APA

Buzzi, M., Epstein, J., Hatem, Z., Juge, N., Mazeaud, C., Lemelle, J. L., & Berte, N. (2026). Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ ( POXIPEN) trial protocol. BJU International. https://doi.org/10.1111/bju.70058

Vancouver

Buzzi M, Epstein J, Hatem Z, Juge N, Mazeaud C, Lemelle JL, et al. Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ ( POXIPEN) trial protocol. BJU International. 2026. doi:10.1111/bju.70058

BibTeX
@article{Buzzi2026,
  author = {Buzzi, Marie and Epstein, Jonathan and Hatem, Zahi and Juge, Nadine and Mazeaud, Charles and Lemelle, Jean-Louis and Berte, Nicolas},
  title = {Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ ( POXIPEN) trial protocol},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70058}
}
Kostenlos starten →